Clinical trial
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy…
NCT02819518 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT02819518 |
|---|---|
| Title | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) |
| Official title | A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355) |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Triple Negative Breast Cancer (TNBC) |
| Intervention type | Biological, Drug |
| Interventions | Pembrolizumab, Nab-paclitaxel, Paclitaxel, Gemcitabine, Carboplatin, Normale Saline Solution |
| Enrollment | 882 |
| Start date | Jul 27, 2016 |
| Primary completion | Jun 15, 2021 |
| Completion | Oct 30, 2023 |
| First posted | Jun 30, 2016 |
| Last update posted | Nov 27, 2024 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: